investing

Tomorrow's Biotech Winners Fuel Fidelity Funds

Fidelity Select Biotechnology and Fidelity Advisor Biotechnology contain a mix of the tried-and-true and the speculative.

Rajiv Kaul hunts for the next big thing in biotech. As manager of the nearly identical Fidelity Select Biotechnology (symbol FBIOX) and Fidelity Advisor Biotechnology (FBTAX) funds, he attends conferences, talks up experts and studies data to find biotech companies with promising drugs.

Once he identifies a potential investment, Kaul tries to predict how successful a drug could be. To measure that, he seeks to determine how many people would take it, how many doctors would prescribe it and what the competitive landscape looks like. Kaul tends to avoid companies with drugs in early-stage testing because there's too much uncertainty about a product's success. "I'd rather wait until the drug gets approved or we have data that shows it works," says Kaul, who has managed both of the biotech funds since October 2005.

That said, both funds hold speculative biotech firms as well as established, profitable outfits. At last report, Select Biotech's three biggest holdings were Gilead Sciences, Biogen Idec and Celgene (all profitable and accounting for 23% of Select's assets). A hefty one-fourth of the fund's assets are in so-called microcaps (companies with market values of $300 million or less), including such money-losing obscurities as ArQule and PolyMedix. "I try to strike a balance between investing in firms that generate a steady stream of cash and those that offer a growing pipeline" of new products, says Kaul.

Once Kaul finds a potential winner, he estimates how much cash flow a company could generate from a drug over ten years. Using these projections, he determines a company's value. If a stock sells for less than his estimate, he buys.

Both funds follow the same strategy and have similar holdings, but they charge different fees. Select Biotech is sold directly to investors and will slap you with a 0.75% charge if you sell shares within 30 days of buying them. Advisor Biotech is only available through financial intermediaries and comes in a variety of share classes with different fee structures.

Over the past year through April 30, Select Biotech returned 19.6%, beating the average health-care fund by nearly 14 percentage points and Standard & Poor's 500-stock index by 15 points. Over the past five years, Select Biotech gained 8.9% annualized, topping the average health fund by an average of 4.0 points per year and the S&P 500 by 7.9 points a year. The Class A shares of Advisor Biotech returned 20.9% over the past year and 8.6% annualized over the past five.

As for biotech's future, the best is yet to come, in Kaul's view. "Science has greatly advanced over the past few years," he says. "We're at an inflection point where there will be a lot of innovation over the next ten years." He also thinks big drug makers will continue to snap up biotech companies to fill empty pipelines with new products.

Follow Jennifer on Twitter or become her fan on Facebook.

ORDER NOW: Buy Kiplinger’s Mutual Funds 2012 special issue for in-depth guidance on the only investments you need.

Most Popular

Your Guide to Roth Conversions
Special Report
Tax Breaks

Your Guide to Roth Conversions

A Kiplinger Special Report
February 25, 2021
11 Best Healthcare Stocks for the Rest of 2021
healthcare stocks

11 Best Healthcare Stocks for the Rest of 2021

The 2020s could be the decade of healthcare stocks. Here are 10 companies and one ETF to watch not just for the remainder of this year, but well beyon…
July 13, 2021
What Is the Social Security COLA?
retirement

What Is the Social Security COLA?

For the average recipient, the 2021 monthly increase doesn't even cover a fill-up at the gas station — but it beats nothing.
July 14, 2021

Recommended

Bankruptcy Filings Chalked Up to COVID-19
investing

Bankruptcy Filings Chalked Up to COVID-19

Bankruptcy filings triggered by COVID-19 difficulties continue to pile up. Here, we look at 32 big-name companies that sought out bankruptcy protectio…
July 27, 2021
Shield Your Portfolio From Inflation
Becoming an Investor

Shield Your Portfolio From Inflation

Use our picks to hedge against rising prices that can eat into your investment returns.
July 27, 2021
15 Best Vanguard Funds for Investors of All Stripes
mutual funds

15 Best Vanguard Funds for Investors of All Stripes

The best Vanguard mutual funds might cover a wide assortment of investing strategies, but they have two things in common: simplicity and cheap fees.
July 23, 2021
The Psychology Behind Your Worst Investment Decisions
investing

The Psychology Behind Your Worst Investment Decisions

We can torpedo our portfolios without even realizing it. Avoiding these seven traps will allow you to make rational investments.
July 22, 2021